Immune optimization in lymphoma. ADC, antibody-drug conjugate; APC, antigen-presenting cell; BiTE, bispecific T-cell engager; CAR T-cell, chimeric antigen receptor T-cell; CTLA-4, cytotoxic T-lymphocyte antigen 4; IMiD, immunomodulatory drug; mAB, monoclonal antibody; NK-cell, natural killer cell; PD-1, programmed cell death-1; Teff, effector T-lymphocyte.